Evaluating Coenzyme Q10 for Chronic Kidney Disease Management
Official title: Clinical Study Evaluating the Role of Coenzyme Q10 as Adjuvant Therapy to Angiotensin Converting Enzyme Inhibitor on Blood Pressure, Proteinuria and Bone Metabolism in Patients With Chronic Kidney Disease
Run by Tanta University · NCT05942027 · Data updated 2026-11-12
This study is testing if adding Coenzyme Q10 to the usual treatment can help people with chronic kidney disease feel better and improve their kidney health.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 44 (estimated) |
| Sponsor | Tanta University Academic / other |
| Drugs / interventions | Chemotherapy |
| Locations | 1 site (Tanta, Capital of Gharbia Governorate.) |
| Status | Recruiting |
| Started | July 15, 2023 |
| Main results expected | July 14, 2026 |
| Study ends | July 15, 2026 |
| Registry record updated | June 19, 2025 |
| Trial ID | NCT05942027 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with non-dialysis chronic kidney disease stages 2-3b, an albumin-to-creatinine ratio of 30 mg/g or higher, and newly diagnosed hypertension.
✕Probably not a fit
Patients with diabetes, heart disease, or other significant comorbidities may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the effects of Coenzyme Q10 as an additional treatment alongside ramipril in patients with chronic kidney disease (CKD) stages 2-3b. It is a randomized, placebo-controlled, double-blind study involving 44 non-dialysis CKD patients, focusing on outcomes such as blood pressure, proteinuria, and bone metabolism over a six-month period. Participants will be stratified and assigned to either the treatment or control group to assess the efficacy of Coenzyme Q10 in improving kidney health and related complications.
Why it matters
Potential benefit: If successful, this study could provide a new therapeutic option to improve kidney function and overall health in patients with chronic kidney disease.
How similar studies have gone: While the use of Coenzyme Q10 in chronic kidney disease is not extensively studied, preliminary findings suggest potential benefits, indicating this approach may be novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years old. * Both sexes. * Patients matched in the duration of CKD. * Non-dialysis chronic kidney disease (CKD) patient with estimated glomerular filtration rate (GFR) 30-89 mL/min/1.73m2 (Stage 2-3b). * Patients with albumin-to-creatinine ratio ≥ 30 mg/g. * Patients with serum Potassium \< 5 mEq/L. * A newly diagnosed patients with hypertension. Exclusion criteria: * Patients with elevated level of potassium ≥ 5 mEq/L. * Patients with diabetes. * Patients with cancer. * Patients with heart disease. * Patients with hepato-biliary disease and other liver diseases. * Patients with kidney stones and urinary tract infection. * Patients with an overactive thyroid gland. * Patients with bleeding disorder. * History of drug allergy to ACEI or ARBs. * Pregnant and breastfeeding women. * Patients with blood pressure ≥180/110 or \<100/60. * Patients on alteplase, azothiopurine, everolimus, sirolimus, lithium, non-steroidal anti-inflammatory drugs (epifenac, tenoxicam, Celecoxib….), potassium retentive diuretics (amiloride, spironolactone), other ACEIs and ARBs will be excluded to avoid possible drug-drug interactions with ramipril. * Patients on omega-3 fatty acids; vitamins (especially A, C, E, K), Chemotherapy and oral anticoagulant (warfarin), cholestyramine, orlistate will be excluded to avoid possible drug interactions that could affect Coenzyme Q10
Where it's running
-
Faculty of Pharmacy Tanta University
Tanta, Capital of Gharbia Governorate., Egypt Recruiting
Study contacts
- Study coordinator: Dina Abdel Hamid, Masters
- Email: pg_87899@pharm.tanta.edu.eg
- Phone: +2001020198970
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Clinical decision support to help consider SGLT2 inhibitors after AKI in type 2 diabetes
This pilot test checks if a CDS message given to clinicians can help decide whether to consider SGLT2 inhibitors for adults with type 2 diabetes who recently had acute kidney injury.
-
Impact of TAVR on kidney function in people with aortic valve disease
This registry tests how trans-catheter aortic valve implantation affects kidney function and the risk of kidney injury in adults with aortic stenosis.
-
Calciphylaxis in people with chronic kidney disease: causes, risks, and early signs
This project will compare adults with chronic kidney disease who develop calciphylaxis to matched CKD patients who do not, collecting clinical data and biological samples to try to find risk factors and early signs.
-
Oral Semaglutide for CKD and MAFLD in adults with diabetes
This study tests whether adding oral semaglutide to standard care can slow kidney and liver disease progression in adults with CKD and MAFLD who have type 2 diabetes.
-
Eye-brain-kidney connections in chronic kidney disease
This study will see if changes in brain network connectivity and retinal blood vessels are linked to cognitive decline and kidney function in adults with chronic kidney disease.
-
Screening for chronic kidney disease
We will see how common chronic kidney disease is among adults followed at a tertiary care center and how many cases were previously undiagnosed.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.